<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889157</url>
  </required_header>
  <id_info>
    <org_study_id>C3421028</org_study_id>
    <nct_id>NCT04889157</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus</brief_title>
  <official_title>AN 8-WEEK, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-06882961 IN CHINESE ADULTS WITH TYPE 2 DIABETES MELLITUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind (sponsor open), placebo controlled study in adult&#xD;
      Chinese participants with T2DM who are receiving metformin as background antihyperglycemic&#xD;
      medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">January 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 23, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours on Days 1, 21, 35 and 56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>0, 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours on Days 1, 21, 35 and 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant change from baseline in vital signs</measure>
    <time_frame>Baseline up to 14 days after last dose (Day 70)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal Electrocardiogram (ECG)</measure>
    <time_frame>Baseline up to 14 days after last dose (Day 70)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent treatment-related adverse events</measure>
    <time_frame>Baseline up to 35 days after last dose (Day 91)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory abnormalities</measure>
    <time_frame>Baseline up to 14 days after last dose (Day 70)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>PF-06882961</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be titrated up to 6 weeks of the 8-week dosing duration to reach desired dose level 120 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06882961</intervention_name>
    <description>Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)</description>
    <arm_group_label>PF-06882961</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with T2DM who are taking metformin monotherapy as their only&#xD;
             antihyperglycemic treatment&#xD;
&#xD;
          -  HbA1c greater than or equal to 7% and less than or equal to 10.5%&#xD;
&#xD;
          -  Total body weight &gt;50 kg (110 lb) with BMI of 22.5 to 45.4 kg/m^2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption&#xD;
&#xD;
          -  Diagnosis of Type 1 diabetes mellitus or secondary forms of diabetes&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina, arterial revascularization, stroke,&#xD;
             heart failure, or transient ischemic attack within 6 months of Screening&#xD;
&#xD;
          -  Any malignancy not considered cured&#xD;
&#xD;
          -  Personal or family history of MTC or MEN2, or participants with suspected MTC&#xD;
&#xD;
          -  Acute pancreatitis or history of chronic pancreatitis&#xD;
&#xD;
          -  Acute gallbladder disease&#xD;
&#xD;
          -  Known history of HIV, hepatitis B, hepatitis C or syphilis, or positive testing of&#xD;
             them&#xD;
&#xD;
          -  Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or&#xD;
             equal to 100 mmHg (diastolic)&#xD;
&#xD;
          -  Clinically relevant ECG abnormalities&#xD;
&#xD;
          -  Positive urine drug test&#xD;
&#xD;
          -  Clinical relevant laboratory tests abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100089</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3421028</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

